Merck launches the latest Herceptin knockoff; Harvard spinout grabs a $5M seed round
→ Merck is the latest big player to field a biosimilar of Herceptin. The pharma giant reported today that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
